Beyond its ability in guiding surgery, FG001 is being evaluated preclinically for another significant benefit; the potential ability to directly eliminate cancerous cells in the body. In addition to helping surgeons see and remove tumors more precisely, FG001 can also function as a photosensitizer as demonstrated pre-clinical. When exposed to specific wave lengths, FG001 can either generate heat and burn the cancer cells (Photothermal Therapy, PTT) or produce molecules that destroy the cancer cells (Photodynamic Therapy, PDT). A technique that spares healthy surrounding tissue from damage, offering a direct therapeutic effect of FG001, further benefiting patients undergoing cancer surgery.

FG001 is ongoing clinical evaluation in oral head and neck cancer in Groningen (CT-005) where multiple regulatory (benefit) clinical endpoints are being investigated. Further, several different pieces of equipment from the world's leading manufactures are being used. The first results needed for regulatory planning and further partnering are anticipated in second half of 2025. It will lead to a combined phase II and II/III trial or a phase II and II trial before seeking approval. The first result from an ongoing investigator-initiated trial in low grade glioma and meningioma has demonstrated that FG001 works well in a broader number of brain tumor indications. 
Following a very positive meeting with FDA, FluoGuide is preparing a submission of the IND for the first of two registration trialsin the USA in high grade glioma (CT-006). The IND is
planned to be submitted in 2025 and first patient enrolled in Q2-26. The funding is secured to deliver results on the above studies.

FluoGuide entered a non-exclusive agreement with the worlds leading MedTech companies; The robot company Intuitive Surgical and minimal invasive company Olympus. 

FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".

For more information on FG001 or FluoGuide's uPAR technology platform, please visit their home page  https://www.fluoguide.com

AcuCort is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient's needs for a user-friendly and effective treatment.

Potential drug candidates are based on existing and well-documented substances in indication areas where there is a great medical need and commercial interest in new and innovative products that bring benefits, such as simple administration. The approved drug is commercialized in partnership with a global network of licensees and distributors. In November 2022, AcuCort signed its first commercial agreement for Zeqmelit® with Kamada Ltd. for the Israeli market. Zeqmelit® is approved in Sweden, Denmark, Norway and Finland for, among other things, the treatment of acute and severe allergic reactions, croup in children, nausea and vomiting during chemotherapy treatment, and for patients with COVID-19 who need complementary oxygen therapy. The drug was previously named ISICORT in Sweden.

Registration processes are ongoing for other prioritized markets and during the year and the commercialization team has been geared up. AcuCort's ambition is to commercialize Zeqmelit® and in the future complement it with other well-proven substances that fit the company's business model in indication areas where there is currently a great medical need for new innovative treatments.

AcuCort AB was founded in 2006 and its head office is located at Medicon Village in Lund, Sweden.

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX).

BiBBInstruments ("BiBB", publ) is a cancer diagnostics company specializing in the
development and marketing of EndoDrill®, the world's first powered endoscopic biopsy
instrument line. Designed for high performance and precision, EndoDrill® provides high-quality tissue samples to enhance diagnostics for a range of cancers, including those affecting the stomach, pancreas, liver, lungs, and bladder. The product portfolio addresses the global market for ultrasound-guided (EUS/EBUS) biopsy instruments, the most advanced and rapidly growing segment in endoscopy. The EndoDrill® system includes sterile,
disposable biopsy instruments and a reusable drive unit.

In 2023, EndoDrill® GI, BiBB's flagship product, received market clearance from the US FDA. In early 2024, the entire EndoDrill® product family obtained CE certification under the European MDR, making EndoDrill® the first and only powered biopsy instrument cleared for market use in both the US and Europe. BiBB began its commercialization phase in early 2025 with its first customer order from a US university hospital. The company aims to form partnerships with global distributors to drive broad sales expansion.

Founded in 2013 by Dr. Charles Walther – a cancer researcher at Lund University and senior clinical pathologist at Skåne University Hospital – BiBB is headquartered at Medicon Village in Lund, Sweden. 

Its shares (Ticker: BIBB) are listed on the Spotlight Stock Market.

Prostatype Genomics is a Swedish based medtech company active in the field of prostate cancer, the most common form of cancer among men in Western Europe and USA. Annually approximately 1.4 million men are diagnosed with prostate cancer globally. Prostatype Genomics is a spin-off from researched performed at Karolinska Institute in Stockholm, Sweden.

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer. By minimizing over- and under-treatment, the quality of life for patients can be improved and substantial resources can be saved within the healthcare systems. Most importantly, Prostatype aids the health care and patients to take the correct treatment decision for each and every individual patient. Prostatype® is a strong example of precision medicine and brings a significant health
economy benefit overall.
Using prostate tissue from the biopsy obtained at the time of diagnosis, the Prostatype® test system combines gene expression information from three stem genes with currently used clinical parameters (PSA, Gleason Score, and Tumor Stage) and calculates the so-called P-score, which shows the risk of actually dying from prostate cancer.

In most countries around the world, over treatment of prostate cancer, especially in low- and
intermediate cases, is and has been a challenge for the health care sector. The risk of dying from prostate cancer in the low- and immediate risk group is very low, but unfortunately a lot of men are still undergoing radical treatments, such as surgery, in many cases causing life long side side effects such as impotence and incontinence. As a consequence, these side effects significantly reduces the quality of life for affected patients and relatives.

Prostatype® is CE-marked and is already commercially launched in selected European countries. Prostatype® is also approved for sales in USA where the subsidiary Prostatype Genomics Inc. holds a so called CLIA-license and have established a partnership with ResearchDX, Irvine, California, as the provider of lab services for the US market.
Prostatype® is expected to be commercially launched in USA during 2025 pending
reimbursement from Medicare, the largest provider of insurance coverage in USA. USA is by far the world's largest market for prognostic biomarkers with an annual value of approximately 200 MUSD.

For more information, you can go the website of Prostatype Genomics here https://www.prostatypegenomics.com/.

Sprint Bioscience is a Swedish biotech company developing small-molecule drug programs with first-in-class potential. The business model is to license these to international pharmaceutical companies in the preclinical phase. By building a continuously growing portfolio, value is created through multiple revenue streams. With the company's unique platform of fragment-based drug development, fragment library, and scrum-inspired process, the company can develop highly interesting and patentable preclinical drug programs in a time- and cost-efficient manner. These are of great interest to international pharmaceutical companies that need new, high-quality innovation for their pre-clinical portfolios.
Sprint Bioscience has successfully entered into several global licensing agreements with various pharmaceutical companies. These companies allocate resources and further develop the programs into finished drugs that can be brought to market and potentially help patients with a great need for new treatment options.
Sprint Bioscience was founded in 2009 and has approximately 40 employees, with labs and offices located in Flemingsberg Life Science Cluster, Stockholm, Sweden. The company has been listed on Nasdaq First North Premier Growth Market (ticker: SPRINT) since 2014.

SenzaGen (Nasdaq Stockholm First North: SENZA) is seizing high-growth opportunities in the in vitro toxicology testing market, driven by the shift from animal testing to human-relevant solutions. With both organic and acquisition-driven growth strategies, the company achieved over 500% growth
from 2020 to 2023, with continued momentum as demand for accurate, ethical alternatives accelerates.

At the core of SenzaGen's offerings is GARD®, a pioneering testing method powered by genomics and machine learning, delivering accurate, human-relevant results. This unique technology meets rigorous industry standards and addresses unmet customer needs, positioning SenzaGen to capture significant value in a rapidly expanding market. With capital dedicated to innovation, acquisitions and R&D, the company is advancing its offerings and scaling operations as it continuing its high growth trajectory. 
For more information, please visit SenzaGen's webate: https://senzagen.com/